A double-blind, placebo-controlled trial of diclofenac/misoprostol in Alzheimer's disease

Neurology

Volumn 53, Issue 1, 1999, Pages 197-201

  Scharf, S ^a   Mander, A ^b   Ugoni, A ^c   Vajda, F ^a   Christophidis, N ^a  

^a ST VINCENT S HOSPITAL   (Australia)

^b Barwon Health   (Australia)

^c UNIVERSITY OF MELBOURNE   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ARTHROTEC; DICLOFENAC; MISOPROSTOL;

AGED; ALZHEIMER DISEASE; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG MIXTURE; DRUG SAFETY; DRUG SCREENING; FEMALE; FOLLOW UP; HUMAN; MALE; PILOT STUDY; PRIORITY JOURNAL; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL;

EID: 0033551547     PISSN: 00283878     EISSN: None     Source Type: Journal    
DOI: 10.1212/wnl.53.1.197     Document Type: Article

References (24)

1. McGeer PL, Schulzer M, McGeer EG. Arthritis and anti-inflammatory agents as possible protective factors for Alzheimer's disease: a review of 17 epidemiologic studies. Neurology 1996;47:425-432.
2. Stewart WF, Kawas C, Corrada M, Metter EJ. Risk of Alzheimer's disease and duration of NSAID use. Neurology 1997;48:626-632.
3. Bauer J, Ganter U, Strauss S, et al. The participation of interleukin-6 in the pathogenesis of Alzheimer's disease. Res Immunol 1992;143:650-657.
4. Rozemuller JM, Stam FC, Eikelenboom P. Acute phase proteins are present in amorphous plaques in the cerebral but not cerebellar cortex of patients with Alzheimer's disease. Neurosci Lett 1990;109:75-78.
5. McGeer PL, Rogers J, McGeer EG. Neuroimmune mechanisms in Alzheimer disease pathogenesis. Alzheimer Dis Assoc Disord 1994;8:149-158.
6. Rogers J, Kirby LC, Hempelman SR, et al. Clinical trial of indomethacin in Alzheimer's disease. Neurology 1993;43: 1609-1611.
7. Hawkey CJ. Non steroidal anti-inflammatory drugs and peptic ulcers. BMJ 1990;300:278-284.
8. Gabriel SE, Jaakimainen L, Bombardier C. Risk for serious gastrointestinal complications related to use of non-steroidal anti-inflammatory drugs: a meta analysis. Ann Intern Med 1991;115:787-796.
9. Henry D, Lim LL, Garcia Rodriguez LA, et al. Variability in risk of gastrointestinal complications with individual nonsteroidal anti-inflammatory drugs: results of a collaborative meta-analysis. BMJ 1996;312:1563-1566.
10. Brooks PM, Day RO. Nonsteroidal anti-inflammatory drugs: differences and similarities. N Engl J Med 1991;324:1716-1725.
11. Zecca L, Ferrario P, Costi P. Determination of diclofenac and its metabolites in plasma and cerebrospinal fluid by high-performance liquid chromatography with electrochemical detection. J Chromatogr 1991;567:425-432.
12. Graham DY, White RH, Moreland LW, et al. Duodenal and gastric ulcer prevention with misoprostol in arthritis patients taking NSAIDs. Ann Intern Med 1993;119:257-262.
13. Silverstein FE, Graham GY, Senior JR, et al. Misoprostol reduces serious gastrointestinal complications in patients with rheumatoid arthritis receiving nonsteroidal anti-inflammatory drugs. Ann Intern Med 1995;123:241-249.
14. American Psychiatric Association. Diagnostic and statistical manual of mental disorders. 4th ed. Washington, DC: American Psychiatric Association, 1994.
15. Folstein MF, Folstein SE, McHugh PR. "Mini-mental state": a practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 1975;12:189-198.
16. Rosen WG, Terry RD, Fuld PA, Katzman R, Peck A. Pathological verification of ischaemic score in differentiation of dementias. Ann Neurol 1980;7:486-488.
17. Rosen WG, Mohs RC, Davis KL. A new rating scale for Alzheimer's disease. Am J Psychiatry 1984;141:1356-1364.
18. Reisberg B, Ferris SH, deLeon MJ, Crook T. The Global Deterioration Scale for assessment of primary degenerative dementia. Am J Psychiatry 1982;139:1136-1139.
19. Clinical global impressions. In: Guy W, ed. ECDEU assessment manual for psychopharmacology. Revised ed. Rockville, MD: US Dept. of Health Education and Welfare, 1976:218-222 (DHEW publication no. [ADM] 76-338).
20. Lawton MP, Brody EM. Assessment of older people: self maintaining and instrumental activities of daily living. Gerontologist 1969;9:179-186.
21. Freiman JA, Chalmers TC, Smith H, Kuebler RR. The importance of beta, the type II error and sample size in the design and interpretation of the randomized controlled trial: survey of 71 "negative" trials. N Engl J Med 1978;299:690-694.
22. Helfgott SM, Sandberg-Cook J, Zakim D, Nestler J. Diclofenac-associated hepatotoxicity. JAMA 1990;264:2660-2662.
23. Shield MJ. Novel applications of misoprostol. Pharmacol Ther 1995;65:125-147.
24. Vane JR, Botting RM. Overview-mechanism of action of anti-inflammatory drugs. In: Vane J, Botting J, Botting R, eds. Improved non-steroid anti-inflammatory drugs: cox-2 enzyme inhibitors. Lancaster, UK: Kluwer Academic Publishers, 1996:1-27.